Basilea berichtet positive Interim-Ergebnisse für Phase-2-Studie FIDES-01 mit Derazantinib bei Patienten mit Gallengangkrebs (iCCA) mit Mutationen oder Amplifikationen des FGFR2-Gens

David Linetsky
Patient Activation

Anil Bhaskar
Unified Customer Experience

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Thomas Shea
Programmatic Marketing

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Frank X. Powers
Healthcare Challenger Brands

Laura Blair
Medication Adherence

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Mike Viscel
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy